Technique of subcutaneous drug administration: correction of mistakes. Literature review and first-hand experience in administering Tafalgin
https://doi.org/10.63769/1683-3295-2025-27-3-143-151
Abstract
The article discusses the features and advantages of subcutaneous administration of drugs using the peptide analgesic Tafalgin as an example, which is used in neurosurgical practice. The focus is on the need for proper technique for performing subcutaneous injections, common mistakes in subcutaneous administration of drugs and their possible consequences. A step-by-step algorithm of actions is provided, which is designed to avoid violating the correct technique for performing subcutaneous injections. In particular, the article discusses the choice of the optimal site for subcutaneous injections, the choice of a syringe and needle for this procedure, the preparation of the skin at the site of the intended injection, and the process of correctly performing a subcutaneous injection itself. Particular attention is paid to the features of subcutaneous administration of Tafalgin. An example of a violation of the technique of subcutaneous injection of Tafalgin is given, which can lead to unintentional intramuscular administration of the drug. The authors present the provisions formulated for the optimal method of administering Tafalgin, which allows minimizing technical errors when performing subcutaneous injections in the clinical work of doctors.
About the Authors
S. A. Ilyin
Clinical Hospital of “Medsi” Group of Companies
Russian Federation
Russian Federation
Sergey A. Ilyin.
Bld. 1, 2 Otradnoye, Krasnogorsk, Moscow Region 143442
E. G. Demyanovskaya
Infectious Clinical Hospital No. 1, Moscow Healthcare Department; Central State Medical Academy, Presidential Administration of Russia
Russian Federation
Russian Federation
Bld. 2, 63 Volokolamskoye Shosse, Moscow 125310; Bld. 1A, 19 Marshala Timoshenko St., Moscow 121359
P. G. Genov
Moscow Clinical Research Center Hospital 52, Moscow Healthcare Department; Associations of Interventional Pain Management
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Apt. 7, 78 Savushkina St., Saint Petersburg 197183
References
1. Abuzarova G.R., Sarmanayeva R.R., Alekseeva G.S., Brazhnicova Y.V. A clinical case of the use of a new selective µ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain. Sovremennaya onkologiya = Journal of Modern Oncology 2022;24(3):313–8. (in Russ.). DOI: 10.26442/18151434.2022.3.201913
2. McKeage J.W., Tan A.Z.H., Taberner A.J. Jet injection through microneedles for large volume subcutaneous delivery. Int J Pharm 2024;667(Pt a):124887. DOI: 10.1016/j.ijpharm.2024.124887
3. Annersten M., Willman A. Performing subcutaneous injections: a literature review. Worldviews Evid Based Nurs 2005;2(3):122–30. DOI: 10.1111/j.1741-6787.2005.00030.x
4. Injection and infusion techniques in the treatment of diabetes mellitus. national guidelines. Russian association of endocrinologists. Available at: https://www.endocrincentr.ru/sites/default/files/all/recomendation/национальные%20рекомендации.%20Техника%20инъекций_РАЭ_2017.pdf (date of access: 02.09.2025). (in Russ.).
5. National standard of Russia ISO 6009–2013. Single-use injection needles. Color coding. Moscow: Standartinform, 2014. (in Russ.).
6. Kurmangulov А.А., Reshetnikova Y.S., Bagirov R.N. et al. Possibilities of visualization as a lean method in the management of medical organizations. Meditsinsky vestnik Yuga Rossii = Medical herald of the south of Russia 2019;10(1):6–12. (in Russ.) DOI: 10.21886/2219-8075-2019-10-1-6-12
7. ISO 6009:2016. Hypodermic needles for single use – сolour coding for identification. Available at: https://www.iso.org/ru/standard/63277.html (date of access: 02.09.2025).
8. Kolesnikov Yu.A., Bespalov A.Yu., Dravolina O.A., Zvartau E.E. Pharmacology of mu-opioids: ways of development. St. Petersburg: Pavlov First Saint Petersburg State Medical University, 2021. 206 p.
9. Van den Beuken-van Everdingen M.H., Hochstenbach L.M., Joosten E.A. et al. update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 2016;51(6):1070–90. DOI: 10.1016/j.jpainsymman.2015.12.340
10. Johnston M., Yu E., Kim J. Perineural invasion and spread in head and neck cancer. expert rev anticancer Ther 2012;12(3):359–71. DOI: 10.1586/era.12.9
11. Usach I., Martinez R., Festini T., Peris J.E. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther 2019;36(11):2986–96. DOI: 10.1007/s12325-019-01101-6
12. Registration certificate for Tafalgin. State register of Medicines. available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingguid=44a02fe4-6c34-4405-a96a-986f4879b61e (date of access: 25.08.2025). (in Russ.).
13. National Institutes of Health Clinical Centre. Patient Education. Giving a subcutaneous injection. Available at: https://patientcareinfusion.com/wp-content/uploads/2020/03/subcutaneous-injection-.pdf (date of access: 25.08.2025).
14. Uysal N. Improvement of nursing students’ learning outcomes through scenario-based skills training. Rev Lat Am Enfermagem 2016;24:e2790. DOI: 10.1590/1518-8345.1310.2790
15. Connelly S.T., Schmidt B.L. Evaluation of pain in patients with oral squamous cell carcinoma. J Pain 2004;5(9):505–10. DOI: 10.1016/j.jpain.2004.09.002
16. Viola M., Sequeira J., Seica R. et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release 2018;286:301–14. DOI: 10.1016/j.jconrel.2018.08.001
17. Tyrosyl-arginyl-phenylalanyl-glycinamide. compound summary. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/127510#section=DSSTox-substance-ID (date of access: 25.08.2025).
18. Koenitz L., Crean A., Vucen S. Pharmacokinetic differences between subcutaneous injection and intradermal microneedle delivery of protein therapeutics. Eur J Pharm Biopharm 2024;204:114517. DOI: 10.1016/j.ejpb.2024.114517
19. Mercadante S. options for treating pain in cancer patients with dysphagia. Drugs 2017;77(6):629–35. DOI: 10.1007/s40265-017-0710-8
20. Kosorukov V.S., Abuzarova G.R., Zakharochkina E.R. et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholy golovy i shei = Head and Neck Tumors (HNT) 2022;12(2):89–107. (in Russ). DOI: 10.17650/2222-1468-2022-12-2-89-107
21. Fürst P., Lundström S., Klepstad P., Strang P. Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center. BMC Palliat Care 2020;19(1):172. DOI: 10.1186/s12904-020-00681-3
Review
For citations:
Ilyin S.A., Demyanovskaya E.G., Genov P.G. Technique of subcutaneous drug administration: correction of mistakes. Literature review and first-hand experience in administering Tafalgin. Russian journal of neurosurgery. 2025;27(3):143-151. (In Russ.) https://doi.org/10.63769/1683-3295-2025-27-3-143-151
Views:
14
Email this article 